SIMPLIFY MANAGED FUTURES STRATEGY ETF

27.08

+0.05000.18%

Post-market: 27.080.00000.00%15:35 EDT

Volume:418.17K

Turnover:11.31M

Market Cap:- -

PE:- -

High:27.11

Open:27.03

Low:26.94

Close:27.03

Loading ...

Overview Company News Filings

Concept

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Press Release: Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition

Dow Jones

·

19 May

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CTA"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CTA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTA\",,,,,undefined,":{"symbol":"CTA","market":"US","secType":"STK","nameCN":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","latestPrice":27.08,"timestamp":1751562000000,"preClose":27.03,"halted":0,"volume":418172,"hourTrading":{"tag":"盘后","latestPrice":27.08,"preClose":27.08,"latestTime":"15:35 EDT","volume":192900,"amount":5223731.5,"timestamp":1751571355899},"delay":0,"floatShares":39075001,"shares":0,"eps":0,"marketStatus":"Market Closed","change":0.05,"latestTime":"07-03 13:00:00 EDT","open":27.03,"high":27.11,"low":26.9417,"amount":11314946.937372,"amplitude":0.006226,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1751875200000},"marketStatusCode":7,"adr":0,"exchange":"AMEX","adjPreClose":27.03,"sharesOutstanding":39075001,"nav":27.09,"aum":1058349051.35,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":27.08,"preClose":27.08,"latestTime":"15:35 EDT","volume":192900,"amount":5223731.5,"timestamp":1751571355899},"volumeRatio":1.6594226259085578,"impliedVol":0.1101,"impliedVolPercentile":0.5},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTA\",,,,,undefined,":{"symbol":"CTA","floatShares":39075001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.6594226259085578,"shares":0,"dividePrice":0,"high":27.11,"amplitude":0.006226,"preClose":27.03,"low":26.9417,"week52Low":25.6601,"pbRate":"--","week52High":30.213,"institutionHeld":0,"latestPrice":27.08,"eps":0,"divideRate":0,"volume":418172,"delay":0,"ttmEps":0,"open":27.03,"prevYearClose":27.89,"prevWeekClose":26.74,"prevMonthClose":26.74,"prevQuarterClose":26.74,"fiveDayClose":26.76,"twentyDayClose":27.25,"sixtyDayClose":28.11},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/CTA\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CTA\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2546751484","title":"ProQR Submits CTA for Phase 1 Study of AX-0810","url":"https://stock-news.laohu8.com/highlight/detail?id=2546751484","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546751484?lang=en_us&edition=fundamental","pubTime":"2025-06-27 05:01","pubTimestamp":1750971684,"startTime":"0","endTime":"0","summary":"ProQR ( ($PRQR) ) just unveiled an update. On June 26, 2025, ProQR Therapeutics announced the submission of a Clinical Trial Application (CTA) to t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/proqr-submits-cta-for-phase-1-study-of-ax-0810?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/proqr-submits-cta-for-phase-1-study-of-ax-0810?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4195","LU2360107671.USD","BK4211","CTA","LU1861217088.USD","LU1861220207.SGD","AX"],"gpt_icon":0},{"id":"2545109460","title":"Animoca Brands has announced the purchase of CTA tokens from the open market","url":"https://stock-news.laohu8.com/highlight/detail?id=2545109460","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545109460?lang=en_us&edition=fundamental","pubTime":"2025-06-21 09:22","pubTimestamp":1750468920,"startTime":"0","endTime":"0","summary":"BlockBeats News, June 21st, According to official sources, Animoca Brands has announced a strategic partnership with the blockchain cross-media ecosystem Cross the Ages. Animoca Brands will support Cross the Ages' upcoming multiplayer action role-playing game, Arise, which is set to be officially launched soon. The company has already begun purchasing CTA tokens from the open market . Additionally, Animoca Brands will provide advice to the project on marketing strategy, audits, and tokenomics.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/299353","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["CTA"],"gpt_icon":0},{"id":"2540719842","title":"Why AbCellera Biologics Stock Raced Nearly 6% Higher Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2540719842","media":"Motley Fool","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540719842?lang=en_us&edition=fundamental","pubTime":"2025-06-03 06:45","pubTimestamp":1748904300,"startTime":"0","endTime":"0","summary":"The company had some encouraging regulatory news to report.It concerned a dermatitis drug the biotech is currently developing.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/06/02/why-abcellera-biologics-stock-raced-nearly-6-highe/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4121","BK4535","CTA","ABCL"],"gpt_icon":0},{"id":"2536812996","title":"Press Release: Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2536812996","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536812996?lang=en_us&edition=fundamental","pubTime":"2025-05-19 20:31","pubTimestamp":1747657860,"startTime":"0","endTime":"0","summary":"-- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology --. -- On-track to file IND and/or CTA for Wilson's Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 --. -- Implementing cost cutting measures to significantly reduce cash needs in advance of key data inflection points --. \"The first-in-human data for PM359 announced today represent a landmark moment for the industry and for our company, demonstrating the unequivocal power of Prime Editing to change patients' lives, with a single dose of PM359 providing potentially curative benefit in a matter of weeks,\" said Allan Reine, M.D., Chief Executive Officer of Prime Medicine. \"These data also reinforce the critical importance of ensuring Prime Medicine is positioned to withstand the challenges of the current environment, so that we can one day deliver the tremendou","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4604","BK4555","03160","BK4585","BK4139","BK4232","CEO","R","BK4588","TM","CFO","BK4022","CTA","BK4099","PRME"],"gpt_icon":0}],"pageSize":4,"totalPage":9,"pageCount":1,"totalSize":33,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CTA\",params:#limit:5,,,undefined,":[{"date":"2025-06-25","symbol":"CTA","amount":0.25,"announcedDate":"2025-06-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-25","defaultRemindTime":1750858200000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-30","payableDate":"2025-06-25","currency":"USD","dateTimestamp":1750824000000,"payDate":"2025-06-30"},{"date":"2025-03-26","symbol":"CTA","amount":0.12,"announcedDate":"2025-03-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-26","defaultRemindTime":1742995800000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-31","payableDate":"2025-03-26","currency":"USD","dateTimestamp":1742961600000,"payDate":"2025-03-31"},{"date":"2024-12-23","symbol":"CTA","amount":0.73816,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-31"},{"date":"2024-09-25","symbol":"CTA","amount":0.3,"announcedDate":"2024-09-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-09-25","defaultRemindTime":1727271000000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-09-30","payableDate":"2024-09-25","currency":"USD","dateTimestamp":1727236800000,"payDate":"2024-09-30"},{"date":"2024-06-25","symbol":"CTA","amount":0.15,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-28","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-06-28"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CTA\",market:\"US\",,,undefined,":[{"executeDate":"2022-08-26","recordDate":"2022-08-29","paymentDate":"2022-08-31","value":0.15,"currency":"USD"},{"executeDate":"2022-09-27","recordDate":"2022-09-28","paymentDate":"2022-09-30","value":0.15,"currency":"USD"},{"executeDate":"2022-10-26","recordDate":"2022-10-27","paymentDate":"2022-10-31","value":0.15,"currency":"USD"},{"executeDate":"2022-11-25","recordDate":"2022-11-28","paymentDate":"2022-11-30","value":0.15,"currency":"USD"},{"executeDate":"2022-12-27","recordDate":"2022-12-28","paymentDate":"2022-12-30","value":1.11096,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CTA\",market:\"US\",delay:false,,,undefined,":{}}}